An antibody heavy chain constant region sequence enhancing activity of an agonistic antibody

A heavy chain constant region and constant region technology, which is applied in the direction of antibodies, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody medical components, etc., can solve the problems that antibody research and development has not been successful, and achieve good development Prospect, good safety profile, enhanced activity effect
CN107474136AActive Publication Date: 2017-12-15SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
9 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Publication Date
2017-12-15

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a heavy chain constant region. The heavy chain constant region includes a CH1 structural domain, a hinge region, a CH2 structural domain and a CH3 structural domain. Sequences of the CH1 structural domain and the hinge region are sequences derived from a CH1 structural domain and a hinge region of human IgG2. Sequences of the CH2 structural domain and the CH3 structural domain are sequences derived from a CH2 structural domain and a CH3 structural domain of human IgG. Affinity between the antibody heavy chain constant region to human Fc[gamma]IIB is equal to or higher than affinity between human IgG1 and the human Fc[gamma]IIB. The I / A ratio of the antibody heavy chain constant region is equal to or higher than the I / A ratio of the human IgG1. An antibody or fusion protein based on the heavy chain constant region is also provided. The antibody heavy chain constant region can significantly enhance agonist activity of the antibody or the fusion protein, and can improve treatment effects of the antibody or the fusion protein on tumor, autoimmunity, and other diseases.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of biopharmaceuticals, in particular to a heavy chain constant region sequence and molecule capable of enhancing the activity of an agonistic antibody or an agonistic molecule (a fusion protein comprising a heavy chain constant region sequence), and a method based on the heavy chain constant region Constructed antibodies or fusion proteins. Background technique

[0002] Molecular targeted therapy based on antibodies and heavy chain constant regions (including Fc fragments), including antibody and heavy chain constant region fusion proteins, has achieved great success in the field of biopharmaceuticals for nearly three decades and continues to be the focus of this field. The treatment of various diseases provides new methods and possibilities. About 30 biotherapeutics (including molecules of heavy chain constant region fusion proteins) based on the heavy chain constant region have been approved, and more than ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More